Arvinas Stock Forecast, Price & News

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Arvinas stock.
View analyst ratings for Arvinas or view top-rated stocks.

Wall Street analysts have given Arvinas a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Arvinas wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Arvinas is scheduled to release its next quarterly earnings announcement on Tuesday, April 27th 2021.
View our earnings forecast for Arvinas.

Arvinas, Inc. (NASDAQ:ARVN) issued its quarterly earnings data on Sunday, February, 28th. The company reported ($0.99) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.78) by $0.21. Arvinas had a negative trailing twelve-month return on equity of 46.99% and a negative net margin of 403.77%.
View Arvinas' earnings history.

Arvinas' stock was trading at $44.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ARVN stock has increased by 63.5% and is now trading at $72.04.
View which stocks have been most impacted by COVID-19.

9 equities research analysts have issued 12-month price objectives for Arvinas' shares. Their forecasts range from $45.00 to $129.00. On average, they expect Arvinas' stock price to reach $105.91 in the next year. This suggests a possible upside of 47.0% from the stock's current price.
View analysts' price targets for Arvinas or view top-rated stocks among Wall Street analysts.

Some companies that are related to Arvinas include Zai Lab (ZLAB), Bausch Health Companies (BHC), Teva Pharmaceutical Industries (TEVA), Grifols (GRFS), Dr. Reddy's Laboratories (RDY), Mirati Therapeutics (MRTX), Jazz Pharmaceuticals (JAZZ), BridgeBio Pharma (BBIO), Ultragenyx Pharmaceutical (RARE), Ascendis Pharma A/S (ASND), ACADIA Pharmaceuticals (ACAD), Ionis Pharmaceuticals (IONS), United Therapeutics (UTHR), Arrowhead Pharmaceuticals (ARWR) and Sarepta Therapeutics (SRPT).
View all of ARVN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

(ARVN) raised $100 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO.

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

Arvinas' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Canaan Partners IX LLC (7.41%), BlackRock Inc. (5.82%), Price T Rowe Associates Inc. MD (4.64%), Avidity Partners Management LP (3.69%), JPMorgan Chase & Co. (3.33%) and Northern Trust Corp (0.81%). Company insiders that own Arvinas stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy, Timothy M Shannon and Ventures Iii LP 5Am.
View institutional ownership trends for Arvinas.

ARVN stock was sold by a variety of institutional investors in the last quarter, including Canaan Partners IX LLC, UBS Asset Management Americas Inc., SG Americas Securities LLC, Morgan Stanley, Squarepoint Ops LLC, Engineers Gate Manager LP, Candriam Luxembourg S.C.A., and First Trust Advisors LP. Company insiders that have sold Arvinas company stock in the last year include Bradley Albert Margus, Ian Taylor, John G Houston, Ronald Peck, and Sean A Cassidy.
View insider buying and selling activity for Arvinas or view top insider-selling stocks.

ARVN stock was purchased by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, BlackRock Inc., JPMorgan Chase & Co., Avidity Partners Management LP, Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Caas Capital Management LP, and Renaissance Technologies LLC. Company insiders that have bought Arvinas stock in the last two years include Briggs Morrison, Ian Taylor, Liam Ratcliffe, and Timothy M Shannon.
View insider buying and selling activity for Arvinas or or view top insider-buying stocks.

Shares of ARVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ARVN stock can currently be purchased for approximately $72.04.

Arvinas has a market capitalization of $3.52 billion and generates $42.98 million in revenue each year. The company earns $-70,290,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis.

Arvinas employs 133 workers across the globe.

The official website for Arvinas is www.arvinas.com.

Arvinas is headquartered at 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511.

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company can be reached via phone at 203-535-1456 or via email at [email protected]